Re: finesand Post# 48225
Finesand:
I've been staying off the boards while developing a more cordial and confidential email relationship with Dr. Pourhassan. So as to answer any ambiguity or questions regarding the depth or breath of the proposed licensing deal I'll share part of his response to me yesterday on this topic.
'Negotiations are almost completed, the final drawing/sorting of all items for the exclusive twelve year rights for sales of Leronlimab for HIV ( Combo, Mono, etc) in United States is a big deal and we're focused on getting it done as soon as possible. We've extended the non-binding term sheet a couple of weeks as we believe we are close to final terms"
I took the "etc" comment to mean revenue from PreP as I posed that question to him. I can't imagine a prospective partner walking away from such a tremendous opportunity. If someone could in fact secure 50% of revenues for $90 million with likely less than 10% upfront - that's just too good to pass up IMO - and frankly a poor outcome for us.- This deal essentially removes any hope of a wholesale buy-out of the company and relegates what was once the attractive goose that lays the golden egg ( and spurned investment) to a much longer drawn out process to see the heady ROI that is often bandied about by board members.
The paltry upfront money possibly gets us through BLA but I'm not certain/confident the announcement of the partnership under these terms moves the PPS needle much. IMO he's betting that GVHD, TNBC or NASH results organically lifts the PPS and provides financing to revenue and up listing to NASDAQ- If that gamble doesn't pay dividends, we'll be swimming in the .20ct's for months to come.
Finesand:
I've been staying off the boards while developing a more cordial and confidential email relationship with Dr. Pourhassan. So as to answer any ambiguity or questions regarding the depth or breath of the proposed licensing deal I'll share part of his response to me yesterday on this topic.
'Negotiations are almost completed, the final drawing/sorting of all items for the exclusive twelve year rights for sales of Leronlimab for HIV ( Combo, Mono, etc) in United States is a big deal and we're focused on getting it done as soon as possible. We've extended the non-binding term sheet a couple of weeks as we believe we are close to final terms"
I took the "etc" comment to mean revenue from PreP as I posed that question to him. I can't imagine a prospective partner walking away from such a tremendous opportunity. If someone could in fact secure 50% of revenues for $90 million with likely less than 10% upfront - that's just too good to pass up IMO - and frankly a poor outcome for us.- This deal essentially removes any hope of a wholesale buy-out of the company and relegates what was once the attractive goose that lays the golden egg ( and spurned investment) to a much longer drawn out process to see the heady ROI that is often bandied about by board members.
The paltry upfront money possibly gets us through BLA but I'm not certain/confident the announcement of the partnership under these terms moves the PPS needle much. IMO he's betting that GVHD, TNBC or NASH results organically lifts the PPS and provides financing to revenue and up listing to NASDAQ- If that gamble doesn't pay dividends, we'll be swimming in the .20ct's for months to come.
1
